US98943L1070 - Common Stock
ZENTALIS PHARMACEUTICALS INC
NASDAQ:ZNTL (5/8/2024, 7:00:03 PM)
After market: 12.43 0 (0%)12.43
+0.12 (+0.97%)
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in New York City, New York and currently employs 156 full-time employees. The company went IPO on 2020-04-03. The firm develops small molecule therapeutics with differentiated product profiles for a broad range of cancers. The company is focused on pipeline of oncology candidates, which include azenosertib, a WEE1 inhibitor for advanced solid tumors, ZN-d5, a B-cell lymphoma 2 (BCL-2) inhibitor for hematologic malignancies and related disorders, and a heterobifunctional degrader of BCL-xL for solid and hematological malignancies.
ZENTALIS PHARMACEUTICALS INC
1359 Broadway, Suite 801
New York City NEW YORK 10018
P: 12124333791
CEO: Anthony Y. Sun
Employees: 156
Website: https://www.zentalis.com/
ZNTL stock results show that Zentalis Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Azenosertib clinical development plan on track with multiple data readouts in gynecological and other cancer types anticipated in the second half of 2024...
NEW YORK and SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company...
Research supports azenosertib’s potential to be highly synergistic in combination with KRAS targeted cancer therapeutics, creating an additional large...
Here you can normally see the latest stock twits on ZNTL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: